Could a fiber from onions and bananas help tame diabetes?
NCT ID NCT07464691
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study will test whether a natural fiber called oligofructose, found in foods like onions and bananas, can help improve blood sugar, cholesterol, and inflammation in Saudi adults with type 2 diabetes. A total of 100 people (50 with diabetes and 50 without) will take either the fiber or a placebo powder twice daily for 12 weeks. Researchers will track changes in blood tests and gut bacteria to see if this simple dietary addition makes a difference.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- oligofructose (a natural dietary fiber)
- What this could lead to
- If it works, this could point toward a simple dietary supplement to help manage blood sugar and reduce inflammation in type 2 diabetes.
- What could go wrong
- This is a small, early-stage trial with only 100 participants. The results may not apply to everyone, and the supplement might not significantly improve diabetes control.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 100 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Sep 2026
An estimate. Start dates often move.
- Expected to finish
-
Dec 2027
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
45 to 60 years
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Saudi, both males and females. * Aged between 45-60 years old * BMI between 25 - 30 kg/m2 * No antibiotic use for the last six months Cases: * Type 2 diabetes. * Duration of diabetes ≥ 5 years * HbA1c ≥ 6.5-8.0 Controls: (subjects with normal OGTT results) * Fasting plasma glucose (FPG) \< 100 mg/dl (5.6mmol/l) * A1C less than 5.7% * 2-hour post-load glucose \< 140 mg/dl (7.8 mmol/l) Exclusion Criteria: 1. Patients with Type 1 diabetes. 2. Pregnant \& breastfeeding females. 3. Any serious disease such as renal or hepatic disease, thyroid functions, coeliac disease, or the presence of gastroparesis. 4. Use of weight-loss treatments within 3 months before inclusion 5. Diabetic patients on acarbose, metformin (\> 1 g/day), and GLP-1 medications. 6. Use of antibiotic drugs for the last 3 months of treatments that influence gut microbiota composition. 7. Bypass surgery, Laparoscopic Sleeve Gastrectomy (LSG), or colon restriction. 8. Chronic gastrointestinal disorder (except irritable bowel syndrome). 9. Patients with a history or symptoms of obstruction or Inflammatory bowel disease 10. Atypical diets (such as vegetarians, vegans, and heavy consumption of dietary supplements). 11. Use of pre/probiotics or fiber supplements within 3 months before inclusion. 12. Any drug that can interfere with food absorption or gut flora, such as chronic consumption of loperamide, cholestyramine, antacids, H2-receptor blockers, proton pump inhibitors, fibrates, corticosteroids, or sex steroids, omega-3 unsaturated fatty acids acid, or anti-inflammatory drugs. 13. Autonomic neuropathy 14. Any immune-compromised disease. 15. Daily alcohol consumption \> 30 g. 16. Involvement in another clinical trial in the past 6 months. 17. Any legal incompetence or mental inability to provide consent.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Gut microbiome are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
King Abdullah bin Abdulaziz University Hospital
Riyadh, 11564, Saudi Arabia
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Custom knee guides put to the test in obese patients
- Could a step board replace the lab bike for fitness testing?
- A pill for obesity? early human trial puts MDR-001 to the test
- Can a weekly shot help people who still struggle with weight after bariatric surgery?
- Can a berry extract help athletes bounce back after brutal workouts?
- Do GLP-1 Weight-Loss drugs change how teens eat and feel?